

# Kathleen M Aguilar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3577199/publications.pdf>

Version: 2024-02-01

9  
papers

116  
citations

1683934  
5  
h-index

1474057  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
2	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 671-690.	1.2	30
3	A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071881669.	1.1	18
4	Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. <i>Gastric Cancer</i> , 2018, 21, 831-844.	2.7	14
5	Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study. <i>Clinical Therapeutics</i> , 2019, 41, 866-881.e7.	1.1	9
6	&lt;p&gt;Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway) Tj ETQq0 0 0 rgBT /Overlock 10 645-656.	0.7	5
7	An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAFâ€mutant advanced melanoma treated with firstâ€line antiâ€PDâ€1 monotherapies or BRAF/MEK inhibitors in a communityâ€based oncology setting. <i>Cancer Medicine</i> , 2020, 9, 7863-7878.	1.3	4
8	SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4544-4544.	0.8	4
9	Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	2